The new company ten23 health is a globally operating contract development and manufacturing Organization (CDMO). It is led by a very experienced team with a proven track record in the field of pharmaceutical product design and development and with an extensive global pharma network. Chief Enabling Officer (CEO) is Prof. Dr. Hanns-Christian Mahler, who was the former Head of Drug Product Services at Lonza. Previous roles have been: Head of Pharmaceutical Development & Supplies at Roche and Principal Scientist at Merck KGaA.
The building which had been taken over from Elanco includes around 4’000 square meters of lab and Office space, and will provide a work environment for 150 FTEs. Benefiting from the talented workforce in the Basel area, ten23 health has hired a team of accomplished leaders, scientists and technicians. Currently ten23 health has around 20 employees including former Elanco employees. Further employees will join the team in the coming months hand in hand with the acquisition of new clients and projects.
Richard Relyea, Partner at 3i and member of ten23 health's Board of Directors, commented: « With our investment in ten23 health, we aim to support the establishment of a uniquely differentiated partner to leading global biotech and pharmaceutical customers in the development, manufacturing and testing of complex and effective injectable biopharmaceutical drugs. »
Hanns-Christian Mahler commented: «There is a significant unmet need in the life sciences market. The number and complexity of molecules and novel therapeutic modalities are increasing. Medical research is facing growing challenges with respect to the stability, usability, and consistent manufacturing of medicines. » He adds: «Our comprehensive offering will allow our clients to focus on the medicine and the patient, whilst leveraging our pharmaceutical expertise and knowledge to plan and de-risk product development to enable commercialization with speed, quality, and success. Our Partners will benefit from shorter development timelines, higher probability of technical success, and ultimately stronger market positioning as a result.»
(Press release / SK)
Picture: Rosental Mitte (Bau- und Verkehrsdepartement BS)
0Comments
More news about
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines